ZA200307216B - Pharmaceutical composition. - Google Patents
Pharmaceutical composition. Download PDFInfo
- Publication number
- ZA200307216B ZA200307216B ZA200307216A ZA200307216A ZA200307216B ZA 200307216 B ZA200307216 B ZA 200307216B ZA 200307216 A ZA200307216 A ZA 200307216A ZA 200307216 A ZA200307216 A ZA 200307216A ZA 200307216 B ZA200307216 B ZA 200307216B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- composition according
- chloro
- acid
- pharmaceutically acceptable
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 18
- 239000000203 mixture Substances 0.000 claims description 55
- 239000004480 active ingredient Substances 0.000 claims description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 239000004094 surface-active agent Substances 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000004359 castor oil Substances 0.000 claims description 18
- 235000019438 castor oil Nutrition 0.000 claims description 18
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 18
- -1 polyoxyethylene Polymers 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 125000005605 benzo group Chemical group 0.000 claims description 14
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 12
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- 150000003626 triacylglycerols Chemical class 0.000 claims description 11
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 8
- 206010019280 Heart failures Diseases 0.000 claims description 8
- 201000001881 impotence Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000004014 plasticizer Substances 0.000 claims description 5
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 3
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 3
- 239000011877 solvent mixture Substances 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 description 9
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000003995 emulsifying agent Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 238000009472 formulation Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000002245 particle Substances 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 125000005456 glyceride group Chemical group 0.000 description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
- RTAIQZZASOBMQE-UHFFFAOYSA-N 4-[4-[(3-chloro-4-hydroxyphenyl)methylamino]-[1]benzothiolo[2,3-d]pyrimidin-2-yl]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1C1=NC(NCC=2C=C(Cl)C(O)=CC=2)=C2C3=CC=CC=C3SC2=N1 RTAIQZZASOBMQE-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229960003511 macrogol Drugs 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 3
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 150000002169 ethanolamines Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- KJJPAVCZQWWWMM-UHFFFAOYSA-N 4-[4-[(3-chloro-4-methoxyphenyl)methylamino]-[1]benzothiolo[2,3-d]pyrimidin-2-yl]cyclohexane-1-carboxylic acid Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(C2CCC(CC2)C(O)=O)=NC2=C1C1=CC=CC=C1S2 KJJPAVCZQWWWMM-UHFFFAOYSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241000640882 Condea Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10107261A DE10107261B4 (de) | 2001-02-16 | 2001-02-16 | Pharmazeutische Zusammensetzung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200307216B true ZA200307216B (en) | 2005-01-13 |
Family
ID=7674278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200307216A ZA200307216B (en) | 2001-02-16 | 2003-09-15 | Pharmaceutical composition. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20040082600A1 (et) |
| EP (1) | EP1385521A2 (et) |
| JP (1) | JP2004519489A (et) |
| KR (1) | KR20030074822A (et) |
| CN (1) | CN1649592A (et) |
| AR (1) | AR032695A1 (et) |
| BR (1) | BR0207271A (et) |
| CA (1) | CA2438401A1 (et) |
| CZ (1) | CZ20032423A3 (et) |
| DE (1) | DE10107261B4 (et) |
| EC (1) | ECSP034769A (et) |
| EE (1) | EE200300378A (et) |
| HU (1) | HUP0303141A3 (et) |
| IL (1) | IL157411A0 (et) |
| MX (1) | MXPA03007318A (et) |
| PE (1) | PE20021039A1 (et) |
| PL (1) | PL364467A1 (et) |
| RU (1) | RU2003127393A (et) |
| SK (1) | SK11352003A3 (et) |
| WO (1) | WO2002072100A2 (et) |
| ZA (1) | ZA200307216B (et) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2007123366A (ru) * | 2004-11-24 | 2008-12-27 | Мерк Энд Ко. | Жидкие и полутвердые фармацевтические препаративные формы для перорального введения замещенного амида |
| WO2013109354A2 (en) * | 2011-12-07 | 2013-07-25 | Texas Southern University | Etravirine formulations and uses thereof |
| JP6943384B2 (ja) * | 2017-03-01 | 2021-09-29 | ヱスビー食品株式会社 | 食品の食感劣化防止用ソフトカプセル、並びに、該食感劣化防止用ソフトカプセル及び食用油を含有する食品 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1766592A (en) * | 1991-06-03 | 1993-01-08 | Merck Sharp & Dohme Limited | Pharmaceutical formulations of a benzodiazepine |
| DE19819023A1 (de) * | 1998-04-29 | 1999-11-04 | Merck Patent Gmbh | Thienopyrimidine |
| DE19928146A1 (de) * | 1999-06-19 | 2000-12-21 | Merck Patent Gmbh | Thienopyrimidine |
| US20030153585A1 (en) * | 2000-01-13 | 2003-08-14 | Sven-Alexander Schreder | Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary |
| DE10001021A1 (de) * | 2000-01-13 | 2001-07-19 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
-
2001
- 2001-02-16 DE DE10107261A patent/DE10107261B4/de not_active Expired - Fee Related
-
2002
- 2002-01-23 US US10/467,788 patent/US20040082600A1/en not_active Abandoned
- 2002-01-23 WO PCT/EP2002/000609 patent/WO2002072100A2/en not_active Application Discontinuation
- 2002-01-23 MX MXPA03007318A patent/MXPA03007318A/es unknown
- 2002-01-23 RU RU2003127393/15A patent/RU2003127393A/ru not_active Application Discontinuation
- 2002-01-23 CN CNA028050061A patent/CN1649592A/zh active Pending
- 2002-01-23 SK SK1135-2003A patent/SK11352003A3/sk not_active Application Discontinuation
- 2002-01-23 BR BR0207271-8A patent/BR0207271A/pt not_active IP Right Cessation
- 2002-01-23 HU HU0303141A patent/HUP0303141A3/hu unknown
- 2002-01-23 JP JP2002571059A patent/JP2004519489A/ja not_active Withdrawn
- 2002-01-23 EP EP02701263A patent/EP1385521A2/en not_active Withdrawn
- 2002-01-23 IL IL15741102A patent/IL157411A0/xx unknown
- 2002-01-23 EE EEP200300378A patent/EE200300378A/et unknown
- 2002-01-23 KR KR10-2003-7010607A patent/KR20030074822A/ko not_active Withdrawn
- 2002-01-23 PL PL02364467A patent/PL364467A1/xx unknown
- 2002-01-23 CZ CZ20032423A patent/CZ20032423A3/cs unknown
- 2002-01-23 CA CA002438401A patent/CA2438401A1/en not_active Abandoned
- 2002-02-15 PE PE2002000135A patent/PE20021039A1/es not_active Application Discontinuation
- 2002-02-15 AR ARP020100516A patent/AR032695A1/es not_active Application Discontinuation
-
2003
- 2003-09-15 EC EC2003004769A patent/ECSP034769A/es unknown
- 2003-09-15 ZA ZA200307216A patent/ZA200307216B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0303141A2 (hu) | 2003-12-29 |
| PL364467A1 (en) | 2004-12-13 |
| RU2003127393A (ru) | 2005-01-20 |
| DE10107261B4 (de) | 2005-03-10 |
| CN1649592A (zh) | 2005-08-03 |
| US20040082600A1 (en) | 2004-04-29 |
| EE200300378A (et) | 2003-10-15 |
| WO2002072100A2 (en) | 2002-09-19 |
| WO2002072100A3 (en) | 2003-11-06 |
| MXPA03007318A (es) | 2003-12-04 |
| PE20021039A1 (es) | 2002-11-14 |
| DE10107261A1 (de) | 2002-09-12 |
| IL157411A0 (en) | 2004-03-28 |
| CA2438401A1 (en) | 2002-09-19 |
| JP2004519489A (ja) | 2004-07-02 |
| SK11352003A3 (sk) | 2003-12-02 |
| AR032695A1 (es) | 2003-11-19 |
| EP1385521A2 (en) | 2004-02-04 |
| HUP0303141A3 (en) | 2006-05-29 |
| CZ20032423A3 (en) | 2004-07-14 |
| BR0207271A (pt) | 2004-03-23 |
| ECSP034769A (es) | 2003-12-24 |
| KR20030074822A (ko) | 2003-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4718653B2 (ja) | シクロスポリンの投与のための親水性二成分系 | |
| EP1303261B1 (en) | Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs | |
| ES2199338T3 (es) | Composiciones farmaceuticas en emulsion, que contienen (3'-desoxi-3'-oxo-mebmt)1-(val)2-ciclosporin. | |
| AU2001277099A1 (en) | Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs | |
| KR19990067603A (ko) | 9-하이드록시리스페리돈 지방산 에스테르의 수성 현탁액 | |
| AU2019363244B2 (en) | Pharmaceutical formulation | |
| JP2019514995A (ja) | グリセリン脂肪酸エステル誘導体又はプロピレングリコール脂肪酸エステル誘導体を含むデュタステリド及びタダラフィルの複合製剤並びにそれを含む経口用カプセル製剤 | |
| JP2006501208A (ja) | 経口投与用シクロスポリン、プロピレングリコールエステルおよび非イオン性界面活性剤含有医薬組成物。 | |
| NZ539046A (en) | Chemotherapeutic self-emulsifying microemulsion compositions of paclitaxel with improved oral bioavailability | |
| TW201306859A (zh) | 醫藥組合物 | |
| ZA200307216B (en) | Pharmaceutical composition. | |
| JP2948111B2 (ja) | 経口投与用油性組成物 | |
| CN111356450A (zh) | Pde5抑制剂的液体填充制剂 | |
| EP3510997B1 (en) | Soft gelatin capsules comprising a suspension of tadalafil | |
| JP2024513509A (ja) | 徐放性脂質前駆製剤 | |
| JP2003521495A (ja) | テルビナフィン含有医薬組成物 | |
| AU2002234622A1 (en) | Pharmaceutical composition containing PDE V inhibitors and surfactants | |
| US20030153585A1 (en) | Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary | |
| JP2002540158A (ja) | レトロウイルスプロテアーゼインヒビター用医薬エマルジョン | |
| KR20070096142A (ko) | 흡수율 증진을 위한 타크로리무스 나노에멀젼 및 그의제조 방법 | |
| EP1435233A1 (en) | Cyclosporin-based pharmaceutical compositions | |
| KR20140102939A (ko) | 포스포다이에스터라제-5 억제제 또는 이의 약학적으로 허용가능한 염을 포함하는 질내 투여용 약학적 조성물 | |
| HK1069763A (en) | Cyclosporin-based pharmaceutical compositions |